

μElectronics Components for Lab- On-Chip Instruments in Molecular Diagnostics

Dr. Thanos M. Demiris
micro2gen Ltd.



ΕΥΡΩΠΑΪΚΗ
ΕΝΩΣΗ
ΕΥΡΩΠΑΪΚΟ ΤΑΜΕΙΟ
ΠΕΡΙΦΕΡΕΙΑΚΗΣ
ΑΝΑΤΥΞΗΣ




ΕΛΛΗΝΙΚΗ ΔΗΜΟΚΡΑΤΙΑ
ΥΠΟΥΡΓΕΙΟ ΠΕΡΙΦΕΡΕΙΑΚΗΣ
ΑΝΑΤΥΞΗΣ


Η παρούσα συσκευή υλοποιήθηκε στο πλαίσιο του έργου «ΕΠΙΧΕΙΡΗΣΙΑΚΟ ΠΡΟΓΡΑΜΜΑ ΕΡΕΥΝΑ ΚΑΙ ΤΕΧΝΟΛΟΓΙΑ» (ΕΠΕΚΕΤ) με τη συγχρηματοδότηση της Ελλάδας και της Ευρωπαϊκής Ένωσης.

- The Market Value of Biochips and microarrays in molecular diagnostics (Jain Pharma-Biotech Report 2011)
 - was **\$2.15 billion** in 2010
 - expected to grow to **\$3.5 billion** by the year 2015
 - and **\$10.6 billion** by the year 2020
 - About **75%** of biochips are **DNA** chips
 - **15%** are **protein** chips
 - 10% use other technologies
 - By 2015, **20% of the biochip market** is expected to be "lab-on-a-chip"
- Involved in this market
 - Large pharmaceutical industry
 - Specialized Enterprises (instrumentation, microfluidics etc.)
 - Numerous research institutions

CORALLIA LOC

State-of-the-art in Prototyping







CORALLIA LOC

Suggested Structure of the Solution

Flexible Software:
Operation by researchers
No Programming necessary



Support for virtually all typical
sensors and actuators on the market
+ innovative proprietary solutions




Ready to use control and readout hardware
Novel control components (machine vision)
Fully flexible and extensible

Goals of the project

- Create a comprehensive state-of-the-art in sensors and actuators
- Define a flexible solution architecture
- Introduce specialized control hardware to reduce costs of deployment and introduce new features
 - Machine vision control of fluidic motion
 - Flexible and accurate position determination
 - Speed measurements (not for continuous flow)
 - Volume measurements (not for continuous flow)
- Introduce various novel biosensors and the corresponding readout modules
 - A new generation of capacitive biosensors
- Use existing biochips but also develop a novel and completely different solution within the project
- Validate using an actual PoC genotyping scenario


CORALLIA LOC

Suggested solution architecture overview




CORALLIA LOC

Hardware Deployment Overview




CORALLIA LOC



CORALLIA LOC

Sample Board: Stepper Control



- Simultaneous Control of
 - 2 medium power motors
 - 5 reduced power motors
- Control of:
 - Syringe pumps
 - Peristaltic pumps
 - Linear Drives
 - Etc.



CORALLIA LoC

Sample Board(s): Temperature Control


- Resistive heaters
 - Simultaneous control of 3 resistive heaters
 - Closed control loop with temperature checks and PID control for temperature estimation
 - Suitable for microheaters (see Corallia LoC)
- Peltier Elements
 - Simultaneous control of 3 peltier
 - Closed control loop with temperature checks and PID control for temperature estimation




CORALLIA LOG

Sample Board: GPIOs

- 8 inputs: voltage up to 24 V, electronically regulated low voltage 0-3.3V
- 16 outputs 1A/24V
 - 6 outputs with PWM
 - 2 out of 6 with electronic reversing of polarity
- Applications:
 - DC motors
 - LEDs for lighting
 - Control signals
 - Etc.






■ Novel Control mechanism


- Initial concept conceived within the framework of the FP7 CDMEDICS project
- Replaces distinct pre-selected control points on a biochip, thus enhancing flexibility
- Reduces mechanical alignment problems
- Significantly reduces costs (feasible with a low-cost camera and low-cost illumination sources)
- Introduces new measurements: speed, volume, bubble formation etc.
- Allows for remote access and technical support while an experiment is running!
- Requires visible wave-front but is also suitable for two-phase microfluidics (not suitable for continuous flow)

- Spartan-6 XC6SLX150TFGG676-3 - 180Hz clock, 1024² frame size
 - 11,657 ms for chip detection
 - 1,456 ms for edge detection
 - 44,83 μ s for flow detection
- Implementation of a frame-grabber
 - Any Camera-link camera can be attached to the system
- Implementation of an image compression IP on hardware
 - For remote access and frame transfer over an Ethernet connection





CORALLIA LOC

Software Concept






CORALLIA LoC

Software Details








CORALLIA LOC

Capacitive Biosensors - Concept





Si Membrane diameter [μm]	125 - 275
Si Membrane thickness [μm]	0.7 - 1.5
Depth of support surface [μm]	0.5 - 1.5
Coverage [$R_{\text{membrane}}/R_{\text{biomaterial}}$]	70%

- Construction of a capacitive biosensor array
 - Consists of 64 independent biosensors
 - Each membrane has a diameter of 150-250 μm




CORALLIA LOC


Specialized deposition technology



- LIFT (laser induced forward transfer): The laser energy is transferred to a donor substrate with an absorbing layer (40 nm Ti)
- The inner energy of the absorption layer is transferred through a heat wave to the thin film of the fluid and a droplet is formed
- The droplet is expanding and then detached in form of a jet




Pipette deposition
 $V = 1\mu\text{L}$



Laser deposition
 $V = \text{pL}$

CORALLIA LOC




A novel biochip integrating the sensors




Metalized polymeric material, integrating microchannels and heaters in one disposable microsystem

CORALLIA LOC

PCR Zone Description





CORALLIA LOC



Micro-Channels

Two sided arrangement



Microthermal elements

- KRAS is usually tethered to cell membranes
- The protein product of the normal KRAS gene performs an essential function in normal tissue signaling, and the mutation of a KRAS gene is an essential step in the development of many cancers
- The most common mutation appears on G12D
- In the case of colorectal cancer the detection of KRAS mutations is used for treatment evaluation with antibodies against EGFR (40% of all cases)

- Creation of a domain-specific overall solution
 - Featuring specialized hardware
 - Novel controls implemented with hardware acceleration
 - Flexible software to replace programming and reduce experimentation time
- To be used as a rapid prototyping tool or
- To be incorporated as IP components in existing solutions
- Validated using real scenarios and setups
- With significant bioproducts
 - Novel biosensors
 - Novel biochips

